Effects of lipopolysaccharide on low- and high-density cultured rabbit vascular smooth muscle cells: differential modulation of nitric oxide release, ERK1/ERK2 MAP kinase activity, protein tyrosine phosphatase activity, and DNA synthesis

Braz J Med Biol Res, February 2002, Volume 35(2) 181-190

Effects of lipopolysaccharide on low- and high-density cultured rabbit vascular smooth muscle cells: differential modulation of nitric oxide release, ERK1/ERK2 MAP kinase activity, protein tyrosine phosphatase activity, and DNA synthesis

L.C. Barbosa de Oliveira¹, C.J. Rocha Oliveira^1,2, D.M. Fries¹, A. Stern³ and H.P. Monteiro¹

¹Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, SP, Brasil

²Disciplina de Biologia Molecular, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil

³Department of Pharmacology, New York University Medical Center, New York, NY, USA

References

^{Correspondence and Footnotes}

Abstract

Previous studies have shown that exogenously generated nitric oxide (NO) inhibits smooth muscle cell proliferation. In the present study, we stimulated rabbit vascular smooth muscle cells (RVSMC) with E. coli lipopolysaccharide (LPS), a known inducer of NO synthase transcription, and established a connection between endogenous NO, phosphorylation/dephosphorylation-mediated signaling pathways, and DNA synthesis. Non-confluent RVSMC were cultured with 0, 5, 10, or 100 ng/ml of the endotoxin. NO release was increased by 86.6% (maximum effect) in low-density cell cultures stimulated with 10 ng/ml LPS as compared to non-stimulated controls. Conversely, LPS (5 to 100 ng/ml) did not lead to enhanced NO production in multilayered (high density) RVSMC. DNA synthesis measured by thymidine incorporation showed that LPS was mitogenic only to non-confluent RVSMC; furthermore, the effect was prevented statistically by aminoguanidine (AG), a potent inhibitor of the inducible NO synthase, and oxyhemoglobin, an NO scavenger. Finally, there was a cell density-dependent LPS effect on protein tyrosine phosphatase (PTP) and ERK1/ERK2 mitogen-activated protein (MAP) kinase activities. Short-term transient stimulation of ERK1/ERK2 MAP kinases was maximal at 12 min in non-confluent RVSMC and was prevented by preincubation with AG, whereas PTP activities were inhibited in these cells after 24-h LPS stimulation. Conversely, no significant LPS-mediated changes in kinase or phosphatase activities were observed in high-density cells. LPS-induced NO generation by RVSMC may switch on a cell density-dependent proliferative signaling cascade, which involves the participation of PTP and the ERK1/ERK2 MAP kinases.

Key words: Nitric oxide, Lipopolysaccharide, Protein tyrosine phosphatases, Mitogen-activated protein kinases, DNA synthesis, Cell density

Introduction

During embryonic life and in the young evolving organism, vascular smooth muscle cells (VSMC) actively divide, secrete extracellular matrix components and have a fibroblast-like appearance. In the adult, smooth muscle cells of the arterial media become highly specialized and non-secretory, acquiring a contractile phenotype and typically remaining at rest (reviewed in 1). A shift from contractile to proliferating VSMC is found during arterial wound healing and in several cardiovascular diseases (2,3). This modulation of VSMC function has been observed not only in vivo but also in cell cultures (1). Among the factors influencing this process are the action of exogenous and/or endogenous nitric oxide (NO) (4-6), and cell density-dependent interactions (7,8). NO is a gaseous free radical produced during the conversion of L-arginine to L-citrulline by constitutively expressed and inducible isoforms of the enzyme NO synthase. The constitutive isoform is present in endothelial cells and cerebellar neurons and is dependent on Ca²⁺/calmodulin. Cytokines and the endotoxin lipopolysaccharide (LPS) from Escherichia coli promote the transcription of the inducible isoform of NO synthase in macrophages and smooth muscle cells (9). NO can function in cell signaling associated with smooth muscle cell relaxation and proliferation (4-6,10,11). It reacts with the iron heme moiety of the soluble form of guanylyl cyclase or with critical thiols in protein kinases, protein phosphatases, and small G proteins (12,13). Furthermore, recent reports have described a role for NO as a mediator/modulator of protein tyrosine phosphorylation (14-16).

Proliferating cells normally display an increase in intracellular phosphotyrosine levels (reviewed in 17). Increased production of NO is found in actively dividing cell populations whenever NO has a positive role in cell growth (18,19). Enhanced total protein tyrosine phosphatase (PTP) activity has been reported in cells harvested at high densities (20). Oxidant inactivation of PTP in neutrophils and mast cells caused activation of ERK1/ERK2, members of the mitogen-activated protein kinase (MAP kinase) family (21,22) that are typically involved in the control of cell cycle progression (23). Specifically, exogenously generated NO was shown to inhibit total PTP activity and also to stimulate ERK1/ERK2 activity in murine fibroblasts and rat mesangial cells (14-16).

Therefore, we investigated whether or not rabbit VSMC (RVSMC) cultured at two cell densities (high-density or multilayered cell cultures, and low-density or non-confluent cell cultures) and stimulated with LPS would produce endogenous NO differentially. We also compared the LPS-induced cell density-dependent NO production with the RVSMC patterns of DNA synthesis, total PTP activity and ERK1/ERK2 MAP kinase activity.

Material and Methods

Material

Cell culture reagents and tissue culture Petri dishes were from Gibco/BRL (Gaithersburg, MD, USA). Protein A-Sepharose CL4B, electrophoresis reagents, LPS (E. coli, tissue culture tested), PDGFbb, sulfanilamide, naphthylethylenediamine dihydrochloride, H₃PO₄, aminoguanidine (AG), phenylmethanesulfonyl fluoride (PMSF), p-nitrophenol phosphate, and phenylarsine oxide were obtained from Sigma (St. Louis, MO, USA). Monoclonal antibody (mAb) 108.1 against the human epidermal growth factor (EGF) receptor was kindly provided by Dr. Yuri Ivaschenko (Rorer Rhone-Poulenc Biotechnology, King of Prussia, PA, USA). Monoclonal antibodies anti-p44/p42 ERK1/ERK2 MAP kinase and anti-phospho-p44/p42 ERK1/ERK2 MAP kinase were purchased from New England Biolabs (Beverly, MA, USA). Oxyhemoglobin (Hb) was obtained from hemolysates of freshly drawn human blood donated by healthy volunteers. Briefly, erythrocytes obtained from 20 ml of blood by centrifugation were washed twice with PBS, pH 7.4, and lysed with an equal volume of ultrapure deionized cold water. The hemolysate was centrifuged, and the supernatant collected and eluted through a Sephadex G-50 column equilibrated with 20 mM HEPES buffer, pH 7.5. The Hb concentration of the eluate was determined by reading the absorbance at 577 nm (e₅₇₇ = 15,300 M^-1 cm^-1) (24). [³H]-Thymidine (specific activity: 92 Ci/mmol) was from Amersham Pharmacia Biotech (Little Chalfont, Buckinghamshire, UK).

Determination of nitrite concentrations in culture supernatants

The concentration of nitrite in cell-free supernatant was determined using Griess reagent (1% sulfanilamide, 0.1% naphthylethylenediamine dihydrochloride and 2% H₃PO₄). Briefly, 300 µl culture supernatant was mixed with 300 µl Griess reagent and incubated in an Eppendorf tube protected from light for 15 min at room temperature. Nitrite concentration was determined with a spectrophotometer with reference to NaNO₂ as standard.

Cell culture and treatments

RVSMC from aorta were kindly donated by Dr. V. Buonassisi (INFAR, Escola Paulista de Medicina, São Paulo, SP, Brazil) (25). Cell cultures were maintained on F-12 medium supplemented with 10% FBS. Cells in multilayers were obtained by seeding 1.4 x 10⁴ cells/cm² in 56-cm² cell culture Petri dishes and incubating for 96 h, with addition of fresh medium after 48 h. Cells at low density were obtained by seeding 0.35 x 10⁴ cells/cm² in 56-cm² cell culture Petri dishes and incubating for 24 h. The cultures were kept at 37ºC in an atmosphere of 5% CO₂ in air and incubated with serum-free medium for 24 h before treatments. Addition of LPS at different concentrations was carried out in F-12 medium containing 5 mM HEPES, 1 mM Ca²⁺ and 0.1% FBS. Cells were then stimulated for 3, 6, 24 and 48 h, and 90-95% cell viability (Trypan blue exclusion) was observed after the different times of incubation. When appropriate, AG (400 µM) or Hb (20 µM) was added to the cell cultures 30 min prior to LPS induction, using cultures not stimulated with the endotoxin as controls. Culture supernatants or cell lysates were obtained by running the experiments in 56-cm² Petri dishes using a final volume of 4 ml stimulation medium.

Measurement of DNA synthesis

RVSMC cultured in 96-well plates at the desired cell densities were stimulated as appropriate. Four hours prior to termination of the assay, 0.5 µCi of [³H]-thymidine was added to each well. After a total stimulation period of 24 h, trypsin was added to the cultures, which were incubated for a further 15 min at 37ºC. The cell suspensions were then collected into fiberglass filters using a cell harvester (LKB-Wallac model 1295-201). After drying, the radioactivity incorporated into the material associated with the filters was measured with a Wallac 1205 Betaplate scintillation counter.

Immunoprecipitation of the EGF receptor

HER 14 cells (NIH 3T3 murine fibroblasts permanently transfected and overexpressing the human EGF receptor) (26), grown in Dulbecco's modified Eagle's medium supplemented with 10% FBS in 75-cm² flasks, were used as a source of human EGF receptor. The cells were solubilized in lysis buffer A (20 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl₂, 1 mM EGTA, 1 µg/ml aprotinin, 1 µg/ml leupeptin, and 1 mM PMSF) for 30 min on ice, and the insoluble material was removed by centrifugation. Pre-clearing was done by gently rotating lysates with added protein A-Sepharose for 1 h at 4ºC, followed by removal of protein A-Sepharose by centrifugation. Pre-cleared lysates were immunoprecipitated with mAb 108.1 against the human EGF receptor conjugated with protein A-Sepharose (27).

Phosphorylation of the EGF receptor in vitro

After washing the immunoprecipitated receptors with kinase buffer (20 mM HEPES, pH 7.5, 5 mM MnCl₂, and 2 mM MgCl₂), 8 µCi of [g-³²P]-ATP was added to the immunoprecipitates and the mixture was incubated for 5 min at 25ºC. The reaction was stopped by the addition of HNTG buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 0.1% Triton X-100) followed by three washes in this buffer. The labeled immunoprecipitate was resuspended in the same buffer and kept at 4ºC for further use.

PTP activity assay

Treated or untreated RVSMC were lysed in buffer A. After 30 min on ice the lysates were centrifuged (10 min, 11,750 g, 4ºC) and the supernatants were used as the source of PTP activity. PTP activity was assayed by mixing 100 µg protein from lysates with a suspension containing immunoprecipitated [³²P]-labeled EGF receptors, prepared essentially as described by Monteiro et al. (27). Reactions were carried out for 30 min at 37ºC with shaking and terminated by centrifugation (11,750 g for 1 min) of the immunoprecipitates. Samples were resolved by SDS-PAGE (7.5% gels) and, after drying, gels were exposed to autoradiographic films. The intensity of the band corresponding to the EGF receptor was determined by enhanced laser densitometry. The PTP activity index was determined according to the expression: 1 - x/R, where x corresponds to the band intensity of the labeled immunoprecipitated EGF receptor incubated with cell lysates and R corresponds to the band intensity of the receptor in the absence of lysate.

Western blot analysis of the ERK1/ERK2 MAP kinase activities

Experimental evidence for LPS-stimulated ERK1/ERK2 activities was obtained by immunoblot analysis using specific anti-phospho-ERK1/ERK2 antibodies. Cells were lysed in 250 µl of lysis buffer A containing phosphatase inhibitors (2 mM sodium orthovanadate, 50 mM sodium fluoride, and 10 mM sodium pyrophosphate). Total cell lysates (50 µg/lane) were resolved on 10% SDS-polyacrylamide gels. Gels were blotted onto nitrocellulose sheets, and blots were probed using mAb against ERK1/ERK2 MAP kinase and phospho-ERK1/ERK2 MAP kinase. After incubation with an appropriate horseradish peroxidase-conjugated secondary antibody, blots were developed using the ECL system (Amersham Pharmacia Biotech).

Statistical analysis

Results are reported as means ± SD. The Student t-test was used for statistical analysis, with the levels of significance set at P<0.01 and P<0.05.

Results

The time course of NO release by non-confluent, low-density RVSMC exposed to LPS (10 ng/ml) indicated that nitrite concentrations in culture supernatants of stimulated cells were significantly (P<0.05) higher than control levels at 24 h (Figure 1A). The slight reduction in baseline nitrite concentrations at 48 h compared with 6 and 24 h is most likely due to the fact that the assay chosen to monitor NO production only measures released nitrite and does not take into account the predictable partial oxidation to nitrate over time (28). The RVSMC 24-h response was dose-dependent, maximal at 10 ng/ml (Figure 1B) and significantly (P<0.05) inhibited by AG (400 µM), a potent inhibitor of inducible NO synthase (29) added to the cultures 30 min prior to introduction of the endotoxin (Figure 1C). By contrast, supernatant nitrite levels of multilayered RVSMC stimulated with either 10 ng/ml or 100 ng/ml LPS were closely similar to those of control cultures over a 24-h period (Figure 1D). Multilayered RVSMC stimulated with these same concentrations for 48 h also failed to produce significant NO above control levels (data not shown).

The patterns of DNA synthesis of non-confluent and multilayered RVSMC elicited by LPS correlated positively with their density-dependent profiles of endogenous NO production. Dose-response curves showed an optimal incorporation of [³H]-thymidine by low-density RVSMC at 10 ng/ml LPS and 24 h. Incorporation levels were comparable to positive control cultures stimulated with the platelet-derived growth factor bb (PDGFbb) (Figure 2A). Conversely, no incorporation of [³H]-thymidine over control levels was observed in high-density RVSMC cultured with different doses of LPS over a 48-h period (Figure 2B). Increasing ten-fold the percentage of FBS in the medium of stimulated and non-stimulated high-density cultures did not alter their pattern of DNA synthesis (data not shown).

The proliferative response of low-density RVSMC was inhibited by 85-90% in the presence of 400 µM AG (Figure 2C). The addition of 20 µM Hb, an extracellular scavenger of NO (30), mitigated the pro-mitogenic effect of endogenous NO, evidenced by inhibition of [³H]-thymidine incorporation by about 65% (Figure 2C).

The 24-h mitogenic response of endotoxin-stimulated low-density RVSMC was accompanied by a significant (P<0.01) 24-h inhibition of PTP activity in cell lysates with respect to control levels. A partial recovery of total PTP activity was obtained when 24-h low-density cell cultures were treated with AG (Figure 3A). Conversely, high-density RVSMC cultures stimulated either with 10 ng/ml or 100 ng/ml LPS showed PTP activity levels similar to those of non-stimulated cells. Noteworthy, PTP activities were two-fold higher in non-stimulated and LPS-stimulated high-density cultures as compared to non-stimulated low-density cultures (Figure 3B).

Changes with time in the activity of the ERK1/ERK2 MAP kinases were observed in low-density RVSMC cultures stimulated with 10 ng/ml LPS. Maximum activation occurred at 12-min stimulation. Preincubation of the cells with 400 µM AG prevented the LPS-stimulated activation of ERK1/ERK2 MAP kinases, suggesting the participation of NO in the process (Figure 4A). By contrast, multilayered RVSMC showed no changes in ERK1/ERK2 MAP kinase activities in response to the incubation with LPS at 5-, 12-, 30-, and 60-min stimulation (Figure 4B).

Figure 1.
Lipopolysaccharide (LPS)-stimulated NO release by rabbit vascular smooth muscle cells (RVSMC). RVSMC were serum-starved for 24 h before incubation with LPS.

A, Non-confluent, low-density RVSMC were exposed to LPS (10 ng/ml) or medium at the times indicated. *P<0.05 compared to medium at the same time (Student t-test). B, Non-confluent, low-density RVSMC were exposed to LPS at the indicated concentrations for 24 h. *P<0.05 compared to medium and other concentrations of LPS (Student t-test). C, Non-confluent, low-density RVSMC were exposed to aminoguanidine (AG, 400 µM) 30 min prior to 24-h stimulation with LPS (10 ng/ml). *P<0.05 compared to cells pretreated with AG and stimulated or not with LPS (Student t-test). D, Multilayered RVSMC were incubated for 24 h with LPS at two different concentrations (10 and 100 ng/ml). After incubation, NO production was estimated as accumulated nitrite in cell culture supernatants. Results are reported as means ± SD of three independent experiments performed in quadruplicate.

[View larger version of this image (32 K GIF file)]

Figure 2.
Effect of lipopolysaccharide (LPS)-induced endogenous NO production on rabbit vascular smooth muscle cell (RVSMC) DNA synthesis. Non-confluent, low-density RVSMC (A) and multilayered cultures (B) were incubated with the indicated concentrations of LPS for 20 and 44 h. Positive control cultures were incubated with platelet-derived growth factor bb (PDGFbb, 10 ng/ml) for the same period of time.

C, Non-confluent, low-density RVSMC were preincubated with aminoguanidine (AG, 400 µM) or hemoglobin (Hb, 20 µM) as indicated, and then stimulated with LPS (10 ng/ml) for 20 and 44 h. Cells were then pulse labeled with [³H]-thymidine (0.5 µCi) for an additional period of 4 h (total time of incubation = 24 and 48 h). Cells were harvested and the radioactivity incorporated was determined as described in Material and Methods. Data are reported as incorporated cpm of [³H]-thymidine (A and B). In C data are reported as percentage of [³H]-thymidine incorporation over control (non-stimulated) levels ± SD (N = 4; assay performed in 10 replicates). A, *P<0.05 compared to cells treated with other concentrations of LPS at 24 h and with all concentrations of LPS at 48 h; ⁺P<0.05 compared to all concentrations of LPS at 24 h except for 10 ng/ml (Student t-test). C, *P<0.05 compared to cells preincubated with other stimuli (Student t-test).

[View larger version of this image (37 K GIF file)]

Figure 3.
Effects of lipopolysaccharide (LPS)-induced NO production on protein tyrosine phosphatase (PTP) activities in rabbit vascular smooth muscle cells (RVSMC). RVSMC were incubated for 24 h with LPS.

A, Non-confluent, low-density RVSMC were exposed to LPS (10 ng/ml). The inducible NO synthase inhibitor aminoguanidine (AG, 400 µM) was added 30 min prior to the incubation with the endotoxin, as indicated. B, Concentration-dependent effects of LPS on RVSMC-associated PTP activities in multilayered cultures. After 24 h, cells were lysed and lysates had their protein concentration determined. Protein contents were matched (100 µg) and PTP activity in lysates was measured as described in Material and Methods. Results are reported as means ± SD of three independent experiments. *P<0.01 compared to medium and ⁺P<0.05 compared to cells pretreated with AG (Student t-test).

[View larger version of this image (10 K GIF file)]

Figure 4.
Time-dependent lipopolysaccharide (LPS) stimulation of rabbit vascular smooth muscle cells (RVSMC) for ERK1/ERK2 activities. Low-density, non-confluent RVSMC (A) and multilayered cultures (B) were stimulated with LPS for the indicated periods of time and ERK1/ERK2 activities were estimated using anti-phospho-ERK1/2 and anti-ERK1/2 antibodies as described in Material and Methods. Representative Western blots (WB) of both situations are shown. AG = aminoguanidine.

[View larger version of this image (66 K GIF file)]

Discussion

Low-density RVSMC, as opposed to high-density cells, were stimulated to release NO following 24-h incubation with 10 ng/ml LPS. This NO response was strongly inhibited by AG, a potent and selective inhibitor of inducible NO synthase (29). It was previously documented that at 400 µM, the concentration used in our study, AG causes over 90% inhibition of inducible NO synthase-elicited cGMP production by VSMC, with no inhibition of constitutive NO synthase activity (29). This suggests that the differential NO response of low-density RVSMC to LPS was dependent on inducible NO synthase activity. The data presented indicate a density-dependent mitogenic response of RVSMC to LPS, which is mediated by NO. Various cell types are known to undergo NO-induced arrest of cell division (4,31,32). Studies on the interaction between VSMC and vascular NO (33) or NO released from NO donors (4-6) have demonstrated that this gaseous free radical has an antimitotic effect, although a cell density-dependent stimulation of NO synthase activity was not specifically addressed. On the other hand, both in vivo and in vitro data support a positive role for NO during cell growth. The NO donor sodium nitroprusside was found to potentiate substance P and PGE₁-induced neovascularization in rabbits, while NO synthase inhibitors abolished endothelial cell proliferation in the same animal model (18). A human colonic adenocarcinoma cell line stably transfected with inducible NO synthase cDNA and presenting sustained release of NO consistently grew faster as a xenograft in nude mice when compared with the wild type and/or transfection controls, and promoted angiogenic activity (34). Furthermore, a positive correlation between cell proliferation, lower state of confluence and induction of NO synthase mRNA was reported by Arnal et al. (35) for endothelial cell cultures. In agreement with these studies, our data on non-confluent LPS-stimulated RVSMC showed significant stimulation of DNA synthesis, which was dependent upon increased production of NO. Interestingly, the inhibition of LPS-stimulated thymidine incorporation by AG and Hb reported herein suggests that inducible NO synthase-generated NO not only acted in an autocrine manner but may also have had a paracrine effect on proliferating low-density RVSMC.

It has been argued that NO-mediated proliferation might involve lower concentrations of this free radical, whereas inhibition of proliferation would be associated with high concentrations of NO (34). Indeed, IL-1-induced lower NO levels did cause a transient (24 h) peak of DNA synthesis by bovine VSMC, which decreased as NO levels increased upon continuous stimulation (6). We showed that RVSMC at low density exhibited significant DNA synthesis after 24-h LPS (10 ng/ml) stimulation, accumulating approximately 7.6 µM nitrite in culture supernatants. However, low-density RVSMC showed an average 40% drop in DNA synthesis after 24-h incubation with 1 mM sodium nitroprusside, that generated 10 µM nitrite (average) in cell-free medium (data not shown). This suggests that pro- and antiproliferative responses for the same state of cell confluence may depend on specific concentrations of available NO.

A reduced growth rate and [³H]-thymidine incorporation reported for normal and transformed animal cells due to overexpression of a cytosolic low-molecular weight PTP (36) lend support to the relationship between PTP activity and mitogenesis. Multilayered RVSMC cultures feature a typical "hills and valleys" morphology (7), presenting basal PTP activities slightly greater than those of 24-h low-density control cultures. Such difference suggests modulation of PTP by cell-to-cell contact. In fact, an enhanced expression of receptor-like PTP with increasing cell density has been described in fibroblasts of different origins (37). PTP-mediated differences in DNA synthesis between low-density and confluent cell cultures stimulated with EGF and PDGF were recently described by Sörby and Östman (38). These authors demonstrated inhibition of thymidine incorporation at high cell density correlating with reduced tyrosine phosphorylation of the growth factor receptors.

All PTP feature a conserved cysteine residue in their catalytic domain, and reactions with NO and other oxidants render the enzyme catalytically inactive (14,27). Therefore, it is reasonable to postulate that the inhibition of total PTP activity presently observed was due to enzyme inactivation by NO. Interestingly, the LPS-stimulated mitogenic response of low-density RVSMC appears to rely on inducible generation of NO and PTP activity. Increased PTP activity at high cell density may act as a restraint on NO generation by inhibiting tyrosine phosphorylation of inducible NO synthase, preventing an increase in enzyme activity (39) and hence precluding a significant mitogenic response. Cell contact, however, must affect other factors directly involved in the control of VSMC DNA synthesis and cell division (8).

Recently, we showed that ERK1/ERK2 are involved in NO signaling in 3T3 fibroblasts stably expressing the human EGF receptor (HER14 cells). Depletion of intracellular levels of glutathione preceded NO-dependent stimulation of ERK1/ERK2 (16). On the other hand, evidence from in vivo experimental models has shown that intracellular levels of glutathione decrease in association with LPS-stimulation of inducible NO synthase expression (40). Therefore, LPS-induced NO generation in VSMC may also decrease intracellular glutathione and promote the activation of ERK1/ERK2.

To conclude, we have shown that LPS-induced endogenous NO generation may switch on a cell density-dependent proliferative signaling cascade in RVSMC, which involves partial inactivation of PTP and activation of ERK1/ERK2 MAP kinases. The predominance of dividing or resting cells as a function of cell density might thus depend on the ability of these cell populations to produce NO. Intracellular levels of NO will regulate PTP activity and the activity of MAP kinases associated with cell division. Our data may have some bearing on pathological states like atherosclerosis, where, despite a putative antiatherogenic role for NO (2), smooth muscle cells of the media that recently migrated to the intima of the vessel wall may respond to inflammatory stimuli by endogenous NO-dependent proliferation, creating a center of cell growth.

Address for correspondence: H.P. Monteiro, Departamento de Bioquímica, Fundação Pró-Sangue, Hemocentro de São Paulo, Av. Enéas C. Aguiar, 155, 1º andar, 05403-000 São Paulo, SP, Brasil. Fax: [phone]. E-mail: [e-mail]

Research supported by FAPESP (No. 96/7927-5), PRONEX/CNPq (No. 569 to H.P. Monteiro), and the National Institute of Environmental Health Sciences (No. ES03425 to A. Stern). L.C. Barbosa de Oliveira was a research fellow of CNPq. Received November 21, 2000. Accepted November 28, 2001.

References

• 1. Thyberg J, Hedin U, Sjolund M, Palmberg L & Bottger BA (1990). Regulation of differentiated properties and proliferation of aortic smooth muscle cells. Arteriosclerosis, 10: 966-990.
• 2. Ross R (1993). The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature, 362: 801-809.
• 3. Schwartz RS, Holmes DR & Topol EJ (1992). The restenosis paradigm revisited: an alternative proposal for mechanisms. Journal of the American College of Cardiology, 20: 1284-1293.
• 4. Garg UC & Hassid A (1989). NO-generating vasodilators and 8-bromo cGMP inhibit mitogenesis and proliferation of cultured vascular smooth muscle cells. Journal of Clinical Investigation, 83: 1774-1777.
• 5. Mooradian DL, Hutsell TC & Keefer LK (1995). NO donor molecules: effect of NO release rate on vascular smooth muscle cell proliferation in vitro Journal of Cardiovascular Pharmacology, 25: 674-678.
• 6. Fukuo K, Inoue T, Morimoto S, Nakahashi T, Yasuda O, Kitano S, Sasada R & Ogihara T (1995). NO mediated cytotoxicity and bFGF release in cultured smooth muscle cells. Journal of Clinical Investigation, 95: 669-676.
• 7. Chamley-Campbell J, Campbell GR & Ross R (1979). The smooth muscle cells in culture. Physiological Reviews, 59: 1-61.
• 8. Sjölund M, Hedin U, Sejersen T, Heldin CH & Thyberg J (1988). Arterial smooth muscle cells express PDGFa mRNA, secrete a PDGF-like mitogen and bind exogenous PDGF in a phenotype- and growth state-dependent manner. Journal of Cell Biology, 106: 403-413.
• 9. Knowles RG & Moncada S (1994). Nitric oxide synthases in mammals. Biochemical Journal, 298: 249-258.
• 10. Kelm M, Feelisch M, Spahr R, Piper HM, Noack E & Schrader J (1988). Quantitative and kinetic characterization of nitric oxide and EDRF released from cultured endothelial cells. Biochemical and Biophysical Research Communications, 154: 236-244.
• 11. Ignarro LJ (1989). Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circulation Research, 65: 1-21.
• 12. Gruetter D, Gruetter CA, Barry BK, Baricos WH, Hyman AL, Kadowitz PJ & Ignarro LJ (1980). Activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and nitrosoguanidine - inhibition by calcium, lanthanum, and other cations, enhancement by thiols. Biochemical Pharmacology, 29: 2943-2950.
• 13. Lander HM, Ogiste JS, Pearce SFA, Levi R & Novogrodsky A (1995). Nitric oxide-stimulated guanine nucleotide exchange on p21Ras. Journal of Biological Chemistry, 270: 7017-7020.
• 14. Peranovich TMS, da Silva AM, Fries DM, Stern A & Monteiro HP (1995). Nitric oxide stimulates tyrosine phosphorylation in murine fibroblasts in the presence and absence of epidermal growth factor. Biochemical Journal, 305: 613-619.
• 15. Callsen D, Sandau KB & Brune B (1999). Nitric oxide and superoxide inhibit platelet-derived growth factor receptor phosphotyrosine phosphatases. Free Radical Biology and Medicine, 26: 1544-1553.
• 16. Monteiro HP, Gruia-Gray J, Peranovich TMS, Barbosa de Oliveira LC & Stern A (2000). Nitric oxide stimulates tyrosine phosphorylation of focal adhesion kinase, Src kinase, and mitogen activated protein kinases in murine fibroblasts. Free Radical Biology and Medicine, 28: 174-182.
• 17. Schlessinger J & Ullrich A (1992). Growth factor signaling by receptor tyrosine kinases. Neuron, 9: 383-391.
• 18. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P & Ledda F (1994). NO mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by SP. Journal of Clinical Investigation, 94: 2036-2044.
• 19. Ghigo D, Arese M, Todde R, Vecchi A, Silvagno F, Costamagna C, Dong QG, Alessio M, Heller R, Soldi R, Trucco F, Garbarino G, Pescarmona G, Mantovani A, Bussolino F & Bosia A (1995). Middle T-antigen-transformed endothelial cells exhibit an increased activity of NO synthase. Journal of Experimental Medicine, 181: 9-19.
• 20. Mansbridge JN, Knuchel R, Knapp AMM & Sutherland RM (1992). Importance of tyrosine phosphatases in the effects of cell-cell contact and microenvironments on EGF-stimulated tyrosine phosphorylation. Journal of Cellular Physiology, 151: 433-442.
• 21. Fialkow L, Chan CK, Rotin D, Grinstein S & Downey GP (1994). Activation of the mitogen-activated protein kinase signaling pathway in neutrophils. Journal of Biological Chemistry, 269: 31234-31242.
• 22. Santini F & Beaven MA (1993). Tyrosine phosphorylation of a mitogen-activated protein kinase-like protein occurs at a late step in exocytosis. Journal of Biological Chemistry, 268: 22716-22722.
• 23. Garrington TP & Johnson GL (1999). Organization and regulation of mitogen-activated protein kinase signaling pathways. Current Opinion in Cell Biology, 11: 211-218.
• 24. Riggs A (1981). Preparation of blood hemoglobins of vertebrates. Methods in Enzymology, 76: 5-28.
• 25. Buonassisi V & Colburn P (1980). Hormone and surface receptors in vascular endothelium. In: Altura BM (Editor), Advances in Microcirculation S. Karger, Basel, Switzerland.
• 26. Honneger AM, Dull TJ, Felder S, Van Obberghen E, Bellot F, Szapary D, Schmidt A, Ullrich A & Schlessinger J (1987). Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell, 51: 199-209.
• 27. Monteiro HP, Ivaschenko Y, Fisher R & Stern A (1991). Inhibition of protein tyrosine phosphatase activity by diamide is reversed by epidermal growth factor in fibroblasts. FEBS Letters, 295: 146-148.
• 28. Laurenti M, Lepoivre M & Tenut JP (1996). Kinetic modeling of the nitric oxide gradient generated in vitro by adherent cells expressing inducible nitric oxide synthase. Biochemical Journal, 314: 109-113.
• 29. Thomas PM, Moore WM, Kasten TP, Nickols GA, Corbett JA, Tilton RG, McDaniel ML, Williamson JR & Currie MG (1993). Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. European Journal of Pharmacology, 233: 119-125.
• 30. Ignarro LJ, Buga GM, Wood KS, Byrns RE & Chaudhuri G (1987). Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proceedings of the National Academy of Sciences, USA, 84: 9265-9269.
• 31. Stemberg J & McGuigan F (1992). NO mediates suppression of T cell responses in murine T. brucei infection. European Journal of Immunology, 22: 2741-2744.
• 32. Maciejewski JP, Carmine S, Tadatsugu S, Cho HJ, Keefeer LK & Nathan CF (1995). NO suppression of human hematopoiesis in vitro Journal of Clinical Investigation, 96: 1085-1092.
• 33. Cooke JP & Tsao PS (1994). Is NO an endogenous antiatherogenic molecule? Arteriosclerosis and Thrombosis, 14: 653-655.
• 34. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC & Moncada S (1995). Roles of NO in tumor growth. Proceedings of the National Academy of Sciences, USA, 92: 4392-4396.
• 35. Arnal JF, Yamin J, Dockery S & Harrison DG (1994). Regulation of endothelial NO synthase mRNA, protein, and activity during cell growth. American Journal of Physiology, 267: C1381-C1388.
• 36. Ruggiero M, Pazzagli C, Rigacci G, Berti A, Chiarugi VP, Pierce JH, Camici G & Ramponi G (1993). Negative growth control by a novel low M(r) phosphotyrosine protein phosphatase in normal and transformed cells. FEBS Letters, 326: 294-298.
• 37. Östman A, Yang Q & Tonks NK (1994). Expression of DEP-1, a receptor-like protein tyrosine-phosphatase, is enhanced with increasing cell density. Proceedings of the National Academy of Sciences, USA, 91: 9680-9684.
• 38. Sörby M & Östman A (1996). Protein tyrosine phosphatase-mediated decrease of epidermal growth factor and platelet-derived growth factor receptor tyrosine phosphorylation in high cell density cultures. Journal of Biological Chemistry, 271: 10963-10966.
• 39. Pan J, Burgher KL, Szczepanik AM & Ringheim G (1996). Tyrosine phosphorylation of inducible nitric oxide synthase: implications for potential post-translational regulation. Biochemical Journal, 314: 889-894.
• 40. Zhang C, Walker LM, Hinson JA & Mayeux PR (2000). Oxidant stress in rat liver after lipopolysaccharide administration: effect of inducible nitric oxide synthase inhibition. Journal of Pharmacology and Experimental Therapeutics, 293: 968-972.

Figure 1. Lipopolysaccharide (LPS)-stimulated NO release by rabbit vascular smooth muscle cells (RVSMC). RVSMC were serum-starved for 24 h before incubation with LPS. A, Non-confluent, low-density RVSMC were exposed to LPS (10 ng/ml) or medium at the times indicated. *P<0.05 compared to medium at the same time (Student t-test). B, Non-confluent, low-density RVSMC were exposed to LPS at the indicated concentrations for 24 h. *P<0.05 compared to medium and other concentrations of LPS (Student t-test). C, Non-confluent, low-density RVSMC were exposed to aminoguanidine (AG, 400 µM) 30 min prior to 24-h stimulation with LPS (10 ng/ml). *P<0.05 compared to cells pretreated with AG and stimulated or not with LPS (Student t-test). D, Multilayered RVSMC were incubated for 24 h with LPS at two different concentrations (10 and 100 ng/ml). After incubation, NO production was estimated as accumulated nitrite in cell culture supernatants. Results are reported as means ± SD of three independent experiments performed in quadruplicate.

Figure 2. Effect of lipopolysaccharide (LPS)-induced endogenous NO production on rabbit vascular smooth muscle cell (RVSMC) DNA synthesis. Non-confluent, low-density RVSMC (A) and multilayered cultures (B) were incubated with the indicated concentrations of LPS for 20 and 44 h. Positive control cultures were incubated with platelet-derived growth factor bb (PDGFbb, 10 ng/ml) for the same period of time. C, Non-confluent, low-density RVSMC were preincubated with aminoguanidine (AG, 400 µM) or hemoglobin (Hb, 20 µM) as indicated, and then stimulated with LPS (10 ng/ml) for 20 and 44 h. Cells were then pulse labeled with [³H]-thymidine (0.5 µCi) for an additional period of 4 h (total time of incubation = 24 and 48 h). Cells were harvested and the radioactivity incorporated was determined as described in Material and Methods. Data are reported as incorporated cpm of [³H]-thymidine (A and B). In C data are reported as percentage of [³H]-thymidine incorporation over control (non-stimulated) levels ± SD (N = 4; assay performed in 10 replicates). A, *P<0.05 compared to cells treated with other concentrations of LPS at 24 h and with all concentrations of LPS at 48 h; ⁺P<0.05 compared to all concentrations of LPS at 24 h except for 10 ng/ml (Student t-test). C, *P<0.05 compared to cells preincubated with other stimuli (Student t-test).

Figure 3. Effects of lipopolysaccharide (LPS)-induced NO production on protein tyrosine phosphatase (PTP) activities in rabbit vascular smooth muscle cells (RVSMC). RVSMC were incubated for 24 h with LPS. A, Non-confluent, low-density RVSMC were exposed to LPS (10 ng/ml). The inducible NO synthase inhibitor aminoguanidine (AG, 400 µM) was added 30 min prior to the incubation with the endotoxin, as indicated. B, Concentration-dependent effects of LPS on RVSMC-associated PTP activities in multilayered cultures. After 24 h, cells were lysed and lysates had their protein concentration determined. Protein contents were matched (100 µg) and PTP activity in lysates was measured as described in Material and Methods. Results are reported as means ± SD of three independent experiments. *P<0.01 compared to medium and ⁺P<0.05 compared to cells pretreated with AG (Student t-test).

Correspondence and Footnotes

Publication Dates

• Publication in this collection
  08 Feb 2002
• Date of issue
  Feb 2002

History

• Accepted
  28 Nov 2001
• Received
  21 Nov 2000